{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=12", "query": { "intervention": "Phase 2 Maximum Tolerated Dose determined in Phase 1", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 507, "total_pages": 51, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T16:02:50.582Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05187624", "title": "A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "RO7428731", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2022-04-05", "completion_date": "2025-05-14", "has_results": false, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-10-14T16:02:50.582Z", "location_count": 2, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05187624" }, { "nct_id": "NCT04291079", "title": "SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "SRK-181", "type": "BIOLOGICAL" }, { "name": "anti-PD-(L)1 antibody therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Scholar Rock, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2020-04-23", "completion_date": "2025-04-14", "has_results": false, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-14T16:02:50.582Z", "location_count": 18, "location_summary": "Fullerton, California • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Celebration", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04291079" }, { "nct_id": "NCT02236013", "title": "A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2015-01-07", "completion_date": "2021-07-26", "has_results": false, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-10-14T16:02:50.582Z", "location_count": 10, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02236013" }, { "nct_id": "NCT04933617", "title": "Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Burkitt Lymphoma", "High-grade B-cell Lymphoma", "T-cell/Histocyte-rich Large B-cell Lymphoma", "Diffuse Large B-Cell Lymphoma (DLBCL)", "Germinal Center B-cell Type (GCB)" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Copanlisib", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Brain", "type": "DIAGNOSTIC_TEST" }, { "name": "18F-FDG - PET", "type": "DIAGNOSTIC_TEST" }, { "name": "CT Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Lumbar Puncture (LP)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-03-24", "completion_date": "2023-11-30", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-10-14T16:02:50.582Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04933617" }, { "nct_id": "NCT00732420", "title": "Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "topotecan", "type": "DRUG" }, { "name": "pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2008-09-24", "completion_date": "2013-06-12", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-14T16:02:50.582Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00732420" }, { "nct_id": "NCT00852189", "title": "Study of EC0489 for the Treatment of Refractory or Metastatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "EC0489, Injection", "type": "DRUG" }, { "name": "EC20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endocyte", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2009-04", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-08-08", "last_synced_at": "2026-10-14T16:02:50.582Z", "location_count": 6, "location_summary": "Lafayette, Indiana • Baltimore, Maryland • Bethesda, Maryland + 3 more", "locations": [ { "city": "Lafayette", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00852189" }, { "nct_id": "NCT00026364", "title": "ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "gefitinib", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2001-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-21", "last_synced_at": "2026-10-14T16:02:50.582Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026364" }, { "nct_id": "NCT02168725", "title": "Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Advanced Solid Tumor" ], "interventions": [ { "name": "briciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Traws Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2014-06", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-10-14T16:02:50.582Z", "location_count": 3, "location_summary": "Aurora, Colorado • Buffalo, New York • Nashville, Tennessee", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Buffalo", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02168725" }, { "nct_id": "NCT00537511", "title": "A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Small Cell" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2008-02-01", "completion_date": "2010-12-01", "has_results": true, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-10-14T16:02:50.582Z", "location_count": 3, "location_summary": "Cleveland, Ohio • Hershey, Pennsylvania • Dallas, Texas", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00537511" }, { "nct_id": "NCT01941316", "title": "Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Carcinoma", "Non Small Cell Lung Carcinoma", "Irinotecan Sensitive Cancers" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cancer Research and Biostatistics Clinical Trials Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2013-11", "completion_date": "2019-07-01", "has_results": true, "last_update_posted_date": "2024-05-09", "last_synced_at": "2026-10-14T16:02:50.582Z", "location_count": 8, "location_summary": "Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01941316" } ] }